VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 24, 2007) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today released new data confirming that the Company's product AL-309 has robust oral bioavailability in preclinical studies. This new data also shows that AL-309 enters the brain and that effective concentrations can be detected for extended periods of time. This information serves to confirm the potential of AL-309 as a highly novel central nervous system drug.
